Compare Gold Fields Limited (GFI) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Novartis AG — how do they compare? Gold Fields Limited trades at $37.31 (market cap $31.87B), while Novartis AG trades at $142.86 (market cap $268.57B). The key difference: Novartis AG is far larger — about 8.4× Gold Fields Limited's market cap, and Gold Fields Limited pays the higher dividend (6%). Which is the better fit depends on your goals — on Pluang, investors hold Gold Fields Limited for 49 Days and Novartis AG for 82 Days on average.
| GFI | NVS | |
|---|---|---|
Market Cap | $31.87B | $268.57B |
Volume | 4,169,651 | 1,532,573 |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $168.62 |
52-Week Low | $31.25 | $121.80 |
Typical Hold Time | 49 Days | 82 Days |
Enterprise Value | $32.47B | $309.89B |
Dividend Yield | 6% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $35.05, down 3.1% amid market reaction to its rejected $27 billion bid for Northern Star. The stock shows a bearish technical signal with key support at $34-$35, while fundamentals remain strong with a 40.76% net margin and low P/E of 7.3. Recent earnings saw mixed results, with one beat and three misses against expectations.
The outlook is balanced: robust cash flow and high profitability support upside toward the $52.75 analyst target, but acquisition uncertainty and technical weakness pose near-term risks. Investor sentiment is cautious pending clarity on M&A strategy and capital allocation.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
